



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

9

Intraocular Inflammation and Uveitis

Last major revision 2015–2016

2017–2018
BCSC
Basic and Clinical
Science Course™

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 10 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2018. *AMA PRA Category 1 Credits*[™] may be claimed only once between June 1, 2015, and the expiration date.

BCSC[®] volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim *AMA PRA Category 1 Credits*[™] upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 9 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. **The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, *Ophthalmology*, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, *Neuro-Ophthalmology*. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved.
No part of this publication may be reproduced without written permission.

Printed in the United States of America.

Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

Section 9

Faculty

Russell W. Read, MD, PhD, *Chair*, Birmingham, Alabama

Nisha Acharya, MD, San Francisco, California

Ralph D. Levinson, MD, Los Angeles, California

P. Kumar Rao, MD, St Louis, Missouri

H. Nida Sen, MD, MHS, Bethesda, Maryland

Jonathan D. Walker, MD, Fort Wayne, Indiana

Daniel V. Vasconcelos-Santos, MD, *Consultant*, Belo Horizonte, Brazil

The Academy wishes to acknowledge the American Uveitis Society (AUS) for recommending faculty members to the BCSC Section 9 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Kelly L. Larkin, MD, Houston, Texas

Vision Rehabilitation Committee: Paul I. Homer, MD, Boca Raton, Florida

Practicing Ophthalmologists Advisory Committee for Education: Dasa V. Gangadhar, MD, *Primary Reviewer*, Wichita, Kansas; Edward K. Isbey III, MD, *Chair*, Asheville, North Carolina; Alice L. Bashinsky, MD, Asheville, North Carolina; David J. Browning, MD, PhD, Charlotte, North Carolina; Robert G. Fante, MD, Denver, Colorado; Bradley D. Fouraker, MD, Tampa, Florida; Steven J. Grosser, MD, Golden Valley, Minnesota; James A. Savage, MD, Memphis, Tennessee



European Board of Ophthalmology: Carlos E. Pavesio, MD, *EBO Chair*, London, United Kingdom; Talin Barisani-Asenbauer, MD, FEBO, *EBO Liaison*, Vienna, Austria; Bahram Bodaghi, MD, PhD, Paris, France; Marc D. de Smet, MD, PhD, Lausanne, Switzerland; Arnd Heiligenhaus, MD, PhD, Münster, Germany; Richard W. J. Lee, PhD, Bristol, United Kingdom; Elisabetta Miserocchi, MD, Milan, Italy; Philip I. Murray, MBBS, DO (RCS), PhD, Birmingham, United Kingdom; Piergiorgio Neri, MD, PhD, FEBO, Ancona, Italy; Miles Stanford, MD, London, United Kingdom

Financial Disclosures

Academy staff members who contributed to the development of this product state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the past 12 months, they have had the following financial relationships:*

Dr Acharya: Santen (C), Xoma (C)

Dr Barisani-Asenbauer: Askin Austria (L), Croma Pharma (S), Laboratoires Thea Austria (L), Novartis Pharmaceuticals (S), Teva Pharmaceutical Industries (C)

Dr Bodaghi: Abbott Medical Optics (C), Allergan (C, S), Bausch + Lomb Surgical (C), Novartis Pharmaceuticals (S), Santen (C), Xoma (C)

Dr Browning: Aerpio Therapeutics (S), Alimera Sciences (C), Diabetic Retinopathy Clinical Research (S), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr de Smet: Allergan (C, L, S), Arnhem Ophthalmic Research (O, P), Bayer Pharmaceuticals (C), Centocor Pharmaceuticals (C, S), GlaxoSmithKline (C), Regeneron Pharmaceuticals (C), Sanofi (C), Santen (C), Thrombogenics (C, L, P, S)

Dr Fante: Ophthalmic Mutual Insurance Company (C)

Dr Fouraker: Addition Technology (C), Alcon Laboratories (C), Keravision (C), Ophthalmic Mutual Insurance Company (C)

Dr Grosser: Ivantis (O)

Dr Isbey: Alcon Laboratories (S), Allscripts (C), Bausch + Lomb (S), Medflow (C)

Dr Larkin: AbbVie Humira (C), Xoma Eyeguard Study (C)

Dr Lee: EMD Serono (C), Genentech (C), UK National Institute for Health Research (S), US Patent Application No. 61/919,404 (P)

Dr Miserocchi: Abbott Immunology (C), Allergan (C), Santen (C)

Dr Neri: AbbVie (L), Bausch + Lomb (C, L), Santen Pharma (C)

Dr Pavesio: Alcon (C), Alimera Sciences (C), Bausch + Lomb (C)

Dr Rao: National Eye Institute (S), Regeneron Pharmaceuticals (S), Servier Laboratories (C)

Dr Read: EyeSight Foundation of Alabama (S), Matthew Family Foundation (S), Research to Prevent Blindness (S)

Dr Savage: Allergan (L)

The other authors and reviewers state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that pro-

duces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Bahram Bodaghi, MD, PhD
Ramana S. Moorthy, MD
Russell N. Van Gelder, MD, PhD
Albert T. Vitale, MD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

American Academy of Ophthalmology Staff

Dale E. Fajardo, *Vice President, Education*
Beth Wilson, *Director, Continuing Professional Development*
Ann McGuire, *Acquisitions and Development Manager*
Stephanie Tanaka, *Publications Manager*
D. Jean Ray, *Production Manager*
Kimberly Torgerson, *Publications Editor*
Beth Collins, *Medical Editor*
Naomi Ruiz, *Editorial Assistant*

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

Contents

- General Introduction xiii
- Objectives 1**
- Introduction 3**
- PART I Ocular Immunology 5**
- Introduction to Ocular Immunology and
Immune-Mediated Eye Disease 7**
- 1 Basic Concepts in Immunology:
Effector Cells and the Innate Immune Response 9**
- Definitions 9
- Components of the Immune System. 9
 - Leukocytes 9
- Overview of the Innate Immune System 12
 - Immunity Versus Inflammation 12
- Triggers of Innate Immunity 13
 - Bacteria-Derived Molecules That Trigger Innate Immunity 13
 - Other Triggers or Modulators of Innate Immunity 16
 - Innate Mechanisms for the Recruitment and Activation of
 - Neutrophils 16
 - Innate Mechanisms for the Recruitment and Activation of
 - Macrophages. 19
- Mediator Systems That Amplify Immune Responses. 22
 - Plasma-Derived Enzyme Systems 22
 - Lipid Mediators 24
 - Cytokines 26
 - Reactive Oxygen Intermediates 29
 - Reactive Nitrogen Products. 29
 - Neutrophil-Derived Granule Products 30
- 2 Immunization and Adaptive Immunity:
The Immune Response Arc and Immune Effectors 31**
- Overview of the Immune Response Arc 32
- Phases of the Immune Response Arc 33
 - Afferent Phase 33
 - Processing Phase 36
 - Effector Phase 38

Immune Response Arc and Primary or Secondary Immune Response 39
 Differences in Primary and Secondary Responses 40
 Homing 40
 Effector Reactivities of Adaptive Immunity 40
 Antibody-Mediated Immune Effector Responses 41
 Lymphocyte-Mediated Effector Responses 44
 Combined Antibody and Cellular Effector Mechanisms 50

3 Ocular Immune Responses 53

Regional Immunity and Immunologic Microenvironments 53
 Immune Responses of the Conjunctiva 53
 Features of the Immunologic Microenvironment 53
 Immunoregulatory Systems 55
 Immune Responses of the Anterior Chamber, Anterior Uvea,
 and Vitreous 56
 Features of the Immunologic Microenvironment 56
 Immunoregulatory Systems 57
 Immune Responses of the Cornea 58
 Features of the Immunologic Microenvironment 58
 Immunoregulatory Systems 59
 Immune Responses of the Retina, RPE, Choriocapillaris, and Choroid 61
 Features of the Immunologic Microenvironment 61
 Immunoregulatory Systems 61

4 Special Topics in Ocular Immunology 63

Animal Models of Human Uveitis 63
 Experimental Autoimmune Uveoretinitis 63
 Endotoxin-Induced Uveitis 63
 Equine Recurrent Uveitis 63
 AIRE-Deficient Mice 64
 IRBP-Specific T-Cell Receptor Transgenic Mice 64
 HLA Associations and Disease 64
 Normal Function of HLA Molecules 64
 Allelic Variation 65
 Disease Associations 66

PART II Intraocular Inflammation and Uveitis 69

5 Clinical Approach to Uveitis 71

Classification of Uveitis 71
 Anterior Uveitis 72
 Intermediate Uveitis 73
 Posterior Uveitis 77
 Panuveitis 77
 Retinal Vasculitis 77
 Categorization by Clinical Course 78

Symptoms of Uveitis	78
Signs of Uveitis	79
Anterior Segment	79
Intermediate Segment	83
Posterior Segment	84
Review of the Patient's Health and Other Associated Factors	84
Differential Diagnosis of Uveitic Entities	85
Epidemiology of Uveitis	85
Laboratory and Medical Evaluation	88
Therapy	93
Medical Management of Uveitis	93
Mydriatic and Cycloplegic Drugs	94
Nonsteroidal Anti-Inflammatory Drugs	94
Corticosteroids	95
Immunomodulatory Medications	100
Surgical Management of Uveitis	109
6 Noninfectious Ocular Inflammatory Diseases	111
Noninfectious Scleritis	111
Treatment of Noninfectious Scleritis	111
Anterior Uveitis	112
Acute Nongranulomatous Anterior Uveitis	112
Chronic Anterior Uveitis	121
Intermediate Uveitis	127
Pars Planitis	128
Multiple Sclerosis	132
Posterior Uveitis	132
Collagen Vascular Diseases	132
Susac Syndrome	139
Inflammatory Chorioretinopathies of Unknown Etiology	140
Panuveitis	166
Sarcoidosis	166
Sympathetic Ophthalmia	171
Vogt-Koyanagi-Harada Syndrome	175
Behçet Disease	182
7 Infectious Ocular Inflammatory Diseases	191
Viral Uveitis	191
Herpesviridae Family	191
Rubella	203
Lymphocytic Choriomeningitis Virus	205
Measles (Rubeola)	206
West Nile Virus	208
Rift Valley Fever	210
Human T-Lymphotropic Virus Type 1	212
Dengue Fever	213
Chikungunya Fever	213
Other Viral Diseases	214

Fungal Uveitis 214
 Ocular Histoplasmosis Syndrome 214
 Protozoal Uveitis 219
 Toxoplasmosis 219
 Helminthic Uveitis 228
 Toxocariasis 228
 Cysticercosis 230
 Diffuse Unilateral Subacute Neuroretinitis 232
 Onchocerciasis 234
 Bacterial Uveitis 236
 Syphilis 236
 Lyme Disease 243
 Leptospirosis 248
 Ocular Nocardiosis 249
 Tuberculosis 250
 Ocular Bartonellosis 255
 Whipple Disease 258
 Infectious Scleritis 259
 Etiology 259
 Clinical Features 259
 Diagnostic Workup 259
 Treatment 260
 Prognosis 260

8 Endophthalmitis 261

Chronic Postoperative Endophthalmitis 261
 Endogenous Endophthalmitis 263
 Endogenous Bacterial Endophthalmitis 263
 Endogenous Fungal Endophthalmitis 265

9 Masquerade Syndromes 273

Neoplastic Masquerade Syndromes 273
 Primary Central Nervous System Lymphoma 273
 Neoplastic Masquerade Syndromes Secondary to Systemic
 Lymphoma 276
 Neoplastic Masquerade Syndromes Secondary to Leukemia 276
 Neoplastic Masquerade Syndromes Secondary to Uveal Lymphoid
 Proliferations 276
 Nonlymphoid Malignancies 277
 Metastatic Tumors 278
 Bilateral Diffuse Uveal Melanocytic Proliferation 278
 Nonneoplastic Masquerade Syndromes 278
 Retinitis Pigmentosa 278
 Ocular Ischemic Syndrome 278
 Chronic Peripheral Rhegmatogenous Retinal Detachment 279
 Intraocular Foreign Bodies 279
 Pigment Dispersion Syndrome 280
 Other Syndromes 280

10	Complications of Uveitis	281
	Calcific Band Keratopathy	281
	Cataracts	281
	Management	282
	Complications	284
	Glaucoma	284
	Uveitic Ocular Hypertension	285
	Uveitic Glaucoma	285
	Corticosteroid-Induced Ocular Hypertension and Glaucoma	286
	Management	287
	Hypotony	288
	Cystoid Macular Edema	289
	Vitreous Opacification and Vitritis	290
	Rhegmatogenous Retinal Detachment	291
	Retinal and Choroidal Neovascularization	291
	Vision Rehabilitation	292
11	Ocular Involvement in AIDS	293
	Ophthalmic Manifestations	293
	Cytomegalovirus Retinitis	294
	Necrotizing Herpetic Retinitis	295
	Toxoplasma Retinochoroiditis	296
	Syphilitic Chorioretinitis	297
	<i>Pneumocystis jirovecii</i> Choroiditis	298
	<i>Cryptococcus neoformans</i> Choroiditis	298
	Multifocal Choroiditis and Systemic Dissemination	299
	External Eye Manifestations	299
	Ocular Adnexal Kaposi Sarcoma	299
	Molluscum Contagiosum	300
	Herpes Zoster	300
	Other Infections	300
	HIV Infection in Resource-Limited Regions of the World	301
	Precautions in the Health Care Setting	301
	Precautions in Ophthalmic Practice	301
	Appendix: Diagnostic Survey for Uveitis	303
	Basic Texts	307
	Related Academy Materials	309
	Requesting Continuing Medical Education Credit	311
	Study Questions	313
	Answer Sheet for Section 9 Study Questions	319
	Answers	321
	Index	327

General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

- 1 Update on General Medicine
- 2 Fundamentals and Principles of Ophthalmology
- 3 Clinical Optics
- 4 Ophthalmic Pathology and Intraocular Tumors
- 5 Neuro-Ophthalmology
- 6 Pediatric Ophthalmology and Strabismus
- 7 Orbit, Eyelids, and Lacrimal System
- 8 External Disease and Cornea
- 9 Intraocular Inflammation and Uveitis
- 10 Glaucoma
- 11 Lens and Cataract
- 12 Retina and Vitreous
- 13 Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.

These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

Videos

This edition of Section 9, *Intraocular Inflammation and Uveitis*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 9. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.

Objectives

Upon completion of BCSC Section 9, *Intraocular Inflammation and Uveitis*, the reader should be able to

- describe the immunologic and infectious mechanisms involved in the development of and complications from uveitis and related inflammatory conditions, including acquired immunodeficiency syndrome
 - identify general and specific pathophysiologic processes in acute and chronic intraocular inflammation that affect the structure and function of the uvea, lens, intraocular spaces, retina, and other tissues
 - differentiate infectious from noninfectious uveitic entities
 - formulate appropriate differential diagnoses for ocular inflammatory disorders
 - based on the differential diagnosis, choose examination techniques and appropriate ancillary studies to differentiate infectious from noninfectious causes
 - describe the principles of medical and surgical management of infectious and noninfectious uveitis and related intraocular inflammation, including indications for, adverse effects of, and monitoring of immunosuppressive drugs
 - describe the structural complications of uveitis, their prevention, and their treatment
 - describe the main principles for differentiating masquerade syndromes from true uveitis and increasing clinical suspicion for these syndromes
-